FOR IMMEDIATE RELEASE

December 13, 2012
AnGes MG, Inc.

The Industry-academia Joint R&D Project on
“Oral DDS Nucleic Acid Drug Using PLGA Nanoparticle Technology”
Receives Technology Prize at the Autumn Annual Meeting and Symposium
of the Society of Powder Technology, Japan (SPTJ)

AnGes MG Inc. (“AnGes”) is pleased to announce that the industry-academia joint R&D project on “Oral Drug Delivery System (DDS) using PLGA nanoparticle technology containing nucleic acid” received the Technology Award at the Autumn Annual Meeting and Symposium of the Society of Powder Technology, Japan (SPTJ). The project has been a collaboration between five parties: Hosokawa Micron Corporation being the project leader, Morishita Jintan Co., Ltd., Osaka University, Graduate School of Medicine (Professor Ryuichi Morishita), Aichi Gakuin, University School of Medicine (Professor Hiromitsu Yamamoto), and AnGes. The purpose of this collaboration project is to research and develop a new drug that enables definitive treatment to intractable inflammatory bowel disease.

A number of researches are being conducted for the DDS of nucleic acid as it is believed to become the next-generation drug. While orally administered nucleic acid drug is highly convenient from the perspective of patient’s QOL no researches have reported any success until now. The development of the key technology required for the formulation of the DDS nucleic acid drug was succeeded by merging the core technologies from each of the five collaboration partners (PLGA nano-sphere, seamless capsules, and NF-kB Decoy Oligo).

The presentation of the report was given by Hosokawa Micron Corporation, as the project representative. Being awarded for the collaborative work in developing oral nucleic acid drug is a confirmation and a recognition of the effort put in by the five partners; and this has brought their research one step closer to achieving their goal. There is a high expectation for the project as it can be a definitive treatment for intractable inflammatory bowel disease; and AnGes, with the other 4 partners, is dedicated to further develop the project with the aim of early commercialization.

This trend will have no effect on the business performance for the fiscal year of 2012.
<R&D Background>
1) Inflammatory bowel disease (ulcerative colitis, Crohn’s disease) often occurs in both men and women in their late teens to early thirties, and frequently causes melena, diarrhea or abdominal pain resulting from erosions or ulcers on the gastrointestinal mucosa. Autoimmune abnormalities and inflammations can be prevented by treatments, but in many cases, large intestine resection will be inevitable after repeated onset and treatment.

2) In recent years, antibody drugs have been developed, and currently more than 1.25 million people in about 100 countries worldwide (approximately 105,000 people in Japan) are benefitted from such treatment. Although patients need to be given intravascular infusions at hospitals and cope with high treatment costs, definitive therapy is still difficult to achieve. Therefore, the establishment of a safe and inexpensive definitive treatment that may reduce patients' burdens is eagerly awaited.

<Development of oral DDS using nucleic acid medicine that enables the world-first definitive treatment>
Given the above background, the 5 industry-academia parties, intend to co-develop a safe and inexpensive definitive treatment that can reduce patients' burden by bringing forth their unique (patented) technologies and combining the advanced therapeutic agent “nucleic acid medicine” (AnGes’s NF-kB Decoy Oligo) with the “nano-DDS technology” and “enteric seamless-capsule technology.”

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

AnGesMG, Inc.
Corporate Communications
TEL:+81-3-5730-2641, FAX:+81-3-5730-2635
http://www.anges-mg.com
Email:info@anges-mg.com